IMV Inc. (NASDAQ:IMV) Q4 2022 Earnings Call Transcript

Now, we are using the Merck test now to understand more precisely what we mean by PD-L1 positivity. And as we look through the entire roster of data, when we get all 30 evaluable patients available to us, we will be able to understand whether or not the benefit that we saw in SPiReL ring-fenced by PD-L1 status holds true in this larger international company-sponsored trial or if we are seeing the benefit across a wider swap of patients. But these are all very, very important things, Doug, that we are constantly interrogating because we are trying to make sure that we pinpoint the right patients for our drug.

Doug Loe: That was good color. Thanks Jeremy.

Jeremy Graff: Thanks Doug.

Andrew Hall: Thanks Doug.

Operator: Thank you. I would now like to turn the conference back to Andrew Hall for closing remarks.

Andrew Hall: Thank you, operator. Well, thank you everyone for your attention this morning. Joe, Brandon, Doug, thank you for the questions. It’s an interesting time in small-cap biotech, and we believe we are pointing the organization in the right direction by the evolution of data that we are creating as well as the exploration of things that we believe is strategically prudent. Thank you everyone for your interest in today’s call and I wish you a great rest of your day. Thank you for your time.

Operator: This concludes today’s conference call. Thank you for participating. You may now disconnect.